» Articles » PMID: 22415520

Genetic Variants of Organic Cation Transporter 1 (OCT1) and OCT2 Significantly Reduce Lamivudine Uptake

Overview
Publisher Wiley
Date 2012 Mar 15
PMID 22415520
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The study sought to investigate the effect of genetic variants of OCT1 (OCT1-P283L and -P341L) and OCT2 (OCT2-T199I, -T201M and -A270S), which were identified in a Korean population, on the transport of lamivudine in vitro and to compare the substrate dependent effects of OCT1 and OCT2 variants with 1-methyl-4-phenylpyridinium (MPP+), tetraethyl ammonium (TEA), metformin and lamivudine as substrates for these transporters. When the transport kinetics of lamivudine uptake in oocytes overexpressing OCT1 and OCT2 wild-type (WT) and variant proteins were measured, lamivudine uptake mediated by OCT1-WT was saturable, and uptake was decreased in oocytes expressing OCT1-P283L and -P341L variants compared with that in OCT1-WT. The Clint of lamivudine in oocytes expressing OCT1-P283L was decreased by 85.1% compared with OCT1-WT, whereas it was decreased by 48.7% in oocytes expressing OCT1-P341L. The Clint of lamivudine in oocytes expressing OCT2-T199I, -T201M and -A270S was decreased by 86.2%, 88.9% and 73.6%, respectively, compared with OCT2-WT. When comparing various substrates such as MPP+, TEA, metformin and lamivudine, the effects of the OCT1 genetic polymorphisms on their uptake were not identical. However, contrary to the case of OCT1, the uptake of MPP+, TEA, metformin and lamivudine in oocytes expressing OCT2-T199I, -T201M and -A270S variants was decreased significantly compared with that in oocytes expressing OCT2-WT. In conclusion, the effect of genetic variations of OCT1 and OCT2 on the uptake of MPP+, TEA, metformin and lamivudine was substrate-dependent.

Citing Articles

Exome Sequence Data of Eight SLC Transporters Reveal That and Variants Alter Metformin Pharmacokinetics and Glycemic Control.

Morales-Rivera M, Alemon-Medina R, Martinez-Hernandez A, Contreras-Cubas C, Altamirano-Bustamante N, Gomez-Garduno J Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459024 PMC: 11510168. DOI: 10.3390/ph17101385.


Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.

Marie S, Frost K, Hau R, Martinez-Guerrero L, Izu J, Myers C Acta Pharm Sin B. 2023; 13(1):1-28.

PMID: 36815037 PMC: 9939324. DOI: 10.1016/j.apsb.2022.08.018.


Stereoselectivity in the Membrane Transport of Phenylethylamine Derivatives by Human Monoamine Transporters and Organic Cation Transporters 1, 2, and 3.

Gebauer L, Rafehi M, Brockmoller J Biomolecules. 2022; 12(10).

PMID: 36291716 PMC: 9599461. DOI: 10.3390/biom12101507.


Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

Yu Z, Mosher E, Bumpus N Annu Rev Pharmacol Toxicol. 2020; 61:565-585.

PMID: 32960701 PMC: 7790910. DOI: 10.1146/annurev-pharmtox-021320-111248.


The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.

Zazuli Z, Duin N, Jansen K, Vijverberg S, Maitland-van der Zee A, Masereeuw R Int J Mol Sci. 2020; 21(18).

PMID: 32927790 PMC: 7554776. DOI: 10.3390/ijms21186627.